Drug profile · INN
ublituximab-xiiy
BRIUMVI
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
ublituximab-xiiy (BRIUMVI) is an FDA-listed pharmaceutical active ingredient. Associated with TG THERAPEUTICS, INC.. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
INN ublituximab-xiiy
Brand BRIUMVI
Route INTRAVENOUS
Formulation INJECTABLE
Originator TG THERAPEUTICS, INC.
Frequently asked questions
What is ublituximab-xiiy?
ublituximab-xiiy (BRIUMVI) is an FDA-listed pharmaceutical active ingredient. Associated with TG THERAPEUTICS, INC.. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for ublituximab-xiiy?
BRIUMVI is a marketed brand name for ublituximab-xiiy. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ublituximab-xiiy?
ublituximab-xiiy has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.